ClinicalTrials.gg

Program

ublituximab

Also written as “Ublituximab”, “Cosibelimab + Ublituximab + Bendamustine combination” and “TGR-1202 + Ublituximab”.

Its studies are mostly in Multiple Sclerosis · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Schizophrenia · Myasthenia Gravis, led by 2 companies.

Furthest: phase 3, since Nov 20, 201423 company-led studies, 7 open or runningNext primary completion: Jan 21, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TG Therapeutics227 open or runningphase 3since Nov 20, 2014Jul 17, 2012Jan 21, 2027phase 3 · NCT05877963
Laboratoire français de Fractionnement et de Biotechnologies10 open or runningphase 1since Mar 31, 2010Mar 31, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Mar 31, 2010.

  1. Nov 18, 2015Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT02612311 · 603 enrolled · United States, Israel, Italy and more
  2. Jan 13, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT02656303 · 116 enrolled · United States, Italy, Poland and more
  3. Apr 10, 2016Phase 2 study in Multiple SclerosisTG Therapeutics · NCT02738775 · 49 enrolled · United States
  4. Jun 28, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT03207256 · 51 enrolled · United States
  5. Sep 7, 20172 phase 3 studies in Relapsing Multiple Sclerosis (RMS)TG Therapeutics · NCT03277261, NCT03277248
  6. Dec 18, 2017Phase 2 study in Multiple Sclerosis, Relapsing-RemittingTG Therapeutics · NCT03381170 · 48 enrolled · United States
  7. Dec 11, 2018Phase 1 study in Lymphoma, B-CellTG Therapeutics · NCT03778073 · 18 enrolled · United States
  8. Jan 9, 2019Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellTG Therapeutics · NCT03801525 · 277 enrolled · United States
  9. Jan 31, 2019Phase 2 study in Lymphoma, FollicularTG Therapeutics · NCT03828448 · 34 enrolled · United States
  10. Oct 16, 2019Phase 3 study in Relapsing Multiple Sclerosis (RMS)TG Therapeutics · NCT04130997 · 1,100 enrolled · United States, Belarus, Croatia and more
  11. May 18, 2023Phase 3 study in Relapsing Multiple SclerosisTG Therapeutics · NCT05877963 · 800 planned · United States, Poland
  12. Oct 1, 20252 phase 3 studies in Relapsing Multiple SclerosisTG Therapeutics · NCT07211633, NCT07220252
  13. Mar 9, 2026Phase 2 study in Multiple SclerosisTG Therapeutics · NCT07503873 · 350 planned · Bosnia and Herzegovina, Georgia, North Macedonia and more
  14. Jun 10, 20262 phase 2 studiesTG Therapeutics · NCT07673744, NCT07680946

Ahead

  1. Jan 21, 2027Primary completion: phase 3 study in Relapsing Multiple SclerosisTG Therapeutics · NCT05877963
  2. Jul 31, 2027Primary completion: phase 2 study in Multiple SclerosisTG Therapeutics · NCT07503873
  3. Jul 1, 2028Primary completion: phase 2 study in Myasthenia GravisTG Therapeutics · NCT07673744
  4. Dec 12, 2028Primary completion: phase 2 study in SchizophreniaTG Therapeutics · NCT07680946

TargetBeta

MS4A1 →read by rule
“A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 ”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07680946Schizophrenia · United States2RecruitingTG TherapeuticsDec 12, 202860
NCT07673744Myasthenia Gravis · United States2RecruitingTG TherapeuticsJul 1, 2028120
NCT07503873Multiple Sclerosis · Bosnia and Herzegovina, Georgia, North Macedonia and more2RecruitingTG TherapeuticsJul 31, 2027350
NCT07220252Relapsing Multiple Sclerosis · United States, Poland, Slovakia3RecruitingTG TherapeuticsJan 1, 2030240
NCT07211633Relapsing Multiple Sclerosis · Bosnia and Herzegovina, Bulgaria, Croatia and more3Active, not recruitingTG TherapeuticsOct 31, 2026360
NCT05877963Relapsing Multiple Sclerosis · United States, Poland3RecruitingTG TherapeuticsJan 21, 2027800
NCT04130997Relapsing Multiple Sclerosis (RMS) · United States, Belarus, Croatia and more3Active, not recruitingTG TherapeuticsMay 31, 20321,100
NCT03828448Lymphoma, Follicular · United States2TerminatedTG TherapeuticsMay 16, 202234
NCT03801525Leukemia, Lymphocytic, Chronic, B-Cell · United States3TerminatedTG TherapeuticsDec 20, 2022277
NCT03778073Lymphoma, B-Cell · United States1TerminatedTG TherapeuticsMay 3, 202218
NCT03381170Multiple Sclerosis, Relapsing-Remitting · United States2CompletedTG TherapeuticsNov 11, 202248
NCT03277261Relapsing Multiple Sclerosis (RMS) · United States3CompletedTG TherapeuticsJul 23, 2020549
NCT03277248Relapsing Multiple Sclerosis (RMS) · United States3CompletedTG TherapeuticsAug 4, 2020545
NCT03207256Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedTG TherapeuticsMay 25, 202251
NCT02738775Multiple Sclerosis · United States2CompletedTG TherapeuticsSep 27, 201749
NCT02656303Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, Poland and more2TerminatedTG TherapeuticsMay 26, 2022116
NCT02612311Leukemia, Lymphocytic, Chronic, B-Cell · United States, Israel, Italy and more3TerminatedTG TherapeuticsFeb 22, 2023603
NCT02301156Leukemia, Lymphocytic, Chronic, B-Cell · United States, Israel3CompletedTG TherapeuticsApr 1, 2020126
NCT02013128Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedTG TherapeuticsDec 201566
NCT02006485Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedTG TherapeuticsOct 2019160
NCT01744912Lymphoma, Non-Hodgkin · United States1TerminatedTG TherapeuticsFeb 7, 201410
NCT01647971Lymphoma, Non-Hodgkin · United States2CompletedTG TherapeuticsMay 201539
NCT01098188Leukemia, Lymphocytic, Chronic, B-Cell · France1CompletedLaboratoire français de Fractionnement et de BiotechnologiesAug 201133

How it is read

Names in the registry

  • “Ublituximab”, 21 entries
  • “Cosibelimab + Ublituximab + Bendamustine combination”, 2 entries
  • “TGR-1202 + Ublituximab”, 1 entry
  • “Ublituximab + TGR-1202”, 1 entry
  • “Ublituximab + TGR-1202 + ibrutinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.